
GRAIL Inc (GRAL) Stock Forecast & Price Target
GRAIL Inc (GRAL) Analyst Ratings
Bulls say
GRAIL is a well-positioned healthcare company with a breakthrough multi-cancer early detection blood test and a positive outlook from the management team, seen through their cautious optimism and positive tone regarding FDA approval and the upcoming ASCO data presentation. The company's recent financial performance also highlights strong growth potential, with a beat on Q1 sales and a 50% year-over-year increase in volume. However, risks to the downside include potential delays or limitations in FDA approval and Medicare reimbursement, as well as any slowdown in the self-pay market.
Bears say
GRAIL is facing challenges in establishing the materiality of its healthcare technology, particularly in terms of ESG performance. Factors such as accuracy and specificity of the blood test, as well as the potential impact on patient outcomes and interventions, are key to the success of the company. However, there may be shifts in what is considered most material in the healthcare industry over time, making it difficult to accurately evaluate GRAIL's overall performance.
This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.
GRAIL Inc (GRAL) Analyst Forecast & Price Prediction
Start investing in GRAIL Inc (GRAL)
Order type
Buy in
Order amount
Est. shares
0 shares